5.520USDMkt Cap: 314.61M USDP/E: 5.81Last update: 2026-05-21
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy fo…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap314.61M USD
Enterprise Value169.52M USD
Revenue (TTM)14.54M USD
Gross Profit2.40M USD
Net Income (TTM)71.18M USD
Revenue/Share0.2660 USD
Last Price5.520 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees226
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)5.81
P/E (Forward)19.26
PEG—
EV/EBITDA-1.88
EV/Revenue11.66
P/S21.64
P/B2.17
EPS (TTM)0.95
EPS (Forward)0.29
52W Range
5.25084% of range5.570
52W High5.570 USD
52W Low5.250 USD
Profitability
Gross Margin41.15%
Oper. Margin-264.14%
EBITDA Margin0.00%
Profit Margin1223.08%
ROE44.71%
ROA32.42%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.33M USD
CapEx (TTM)7.97M USD
FCF Margin-389.20%
FCF Yield-17.99%
Net Debt-145.10M USD
Net Debt/EBITDA1.61
Balance Sheet
Debt/Equity0.16
Current Ratio5.89
Quick Ratio5.64
Book Value/Sh2.549 USD
Cash/Share2.952 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateJul 5, 2022
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)19.71 USD
Target Range14.00 USD – 28.00 USD
# Analysts7
Ownership
Shares Out.57.00M
Float36.34M
Insiders16.74%
Institutions70.54%
Short Interest
Short Ratio16.9d
Short % Float31.12%
Short % Out.28.98%
Shares Short16.49M
Short (prev mo.)15.84M
Technical
SMA 505.147 (+7.3%)
SMA 2005.351 (+3.2%)
Beta1.34
S&P 52W Chg28.31%
Avg Vol (30d)782.70K
Avg Vol (10d)1.30M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—